Literature DB >> 23345508

Diversity of ubiquitin and ISG15 specificity among nairoviruses' viral ovarian tumor domain proteases.

Glenn C Capodagli1, Michelle K Deaton, Erica A Baker, Ryan J Lumpkin, Scott D Pegan.   

Abstract

Nairoviruses are responsible for numerous diseases that affect both humans and animal. Recent work has implicated the viral ovarian tumor domain (vOTU) as a possible nairovirus virulence factor due to its ability to edit ubiquitin (Ub) bound to cellular proteins and, at least in the case of Crimean-Congo hemorrhagic fever virus (CCHFV), to cleave the Ub-like protein interferon-stimulated gene 15 (ISG15), a protein involved in the regulation of host immunity. The prospective roles of vOTUs in immune evasion have generated several questions concerning whether vOTUs act through a preserved specificity for Ub- and ISG15-conjugated proteins and where that specificity may originate. To gain insight into the substrate specificity of vOTUs, enzymological studies were conducted on vOTUs from Dugbe, CCHFV, and Erve nairoviruses. These studies revealed that vOTUs originating from different nairoviruses display a significant divergence in their preference toward Ub and ISG15. In addition, a recently identified vOTU from turnip yellow mosaic tymovirus was evaluated to elucidate any possible similarities between vOTUs originating from different viral families. Although possessing a similar preference for certain polymeric Ub moieties, its activity toward Ub in general was significantly less then those of nairoviruses. Lastly, the X-ray crystallographic structure of the vOTU from the Dugbe nairovirus was obtained in complex with Ub to reveal structural commonalities of vOTUs originating from nairoviruses. The structure suggests that divergences between nairovirus vOTUs specificity originate at the primary structural level. Comparison of this structure to that originating from CCHFV identified key residues that infer the substrate specificity of vOTUs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345508      PMCID: PMC3624237          DOI: 10.1128/JVI.03252-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein.

Authors:  Troy Eugene Messick; Nathaniel Scott Russell; Ayaka Jennifer Iwata; Kathryn Lorenz Sarachan; Ramin Shiekhattar; John R Shanks; Francisca E Reyes-Turcu; Keith D Wilkinson; Ronen Marmorstein
Journal:  J Biol Chem       Date:  2008-02-12       Impact factor: 5.157

2.  The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity.

Authors:  Naina Barretto; Dalia Jukneliene; Kiira Ratia; Zhongbin Chen; Andrew D Mesecar; Susan C Baker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Nairobi sheep disease virus, an important tick-borne pathogen of sheep and goats in Africa, is also present in Asia.

Authors:  Beate I Marczinke; Stuart T Nichol
Journal:  Virology       Date:  2002-11-10       Impact factor: 3.616

4.  Phosphorylation-dependent activity of the deubiquitinase DUBA.

Authors:  Oscar W Huang; Xiaolei Ma; JianPing Yin; Jeremy Flinders; Till Maurer; Nobuhiko Kayagaki; Qui Phung; Ivan Bosanac; David Arnott; Vishva M Dixit; Sarah G Hymowitz; Melissa A Starovasnik; Andrea G Cochran
Journal:  Nat Struct Mol Biol       Date:  2012-01-15       Impact factor: 15.369

5.  Isolation of Ganjam virus from a human case of febrile illness: a report of a laboratory infection and serological survey of human sera from three different states of India.

Authors:  C N Dandawate; T H Work; J K Webb; K V Shah
Journal:  Indian J Med Res       Date:  1969-06       Impact factor: 2.375

6.  Investigation of tick-borne viruses as pathogens of humans in South Africa and evidence of Dugbe virus infection in a patient with prolonged thrombocytopenia.

Authors:  F J Burt; D C Spencer; P A Leman; B Patterson; R Swanepoel
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

7.  Molecular epidemiology of Crimean-Congo hemorrhagic fever virus in Turkey: occurrence of local topotype.

Authors:  Etem Ozkaya; Ender Dincer; Ahmet Carhan; Yavuz Uyar; Mustafa Ertek; Chris A Whitehouse; Aykut Ozkul
Journal:  Virus Res       Date:  2010-01-15       Impact factor: 3.303

8.  Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains.

Authors:  Masato Akutsu; Yu Ye; Satpal Virdee; Jason W Chin; David Komander
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-25       Impact factor: 11.205

9.  Inhibition of interferon induction and action by the nairovirus Nairobi sheep disease virus/Ganjam virus.

Authors:  Barbara Holzer; Siddharth Bakshi; Anne Bridgen; Michael D Baron
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

Review 10.  Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis.

Authors:  Friedemann Weber; Ali Mirazimi
Journal:  Cytokine Growth Factor Rev       Date:  2008-11-21       Impact factor: 7.638

View more
  28 in total

1.  Insights into the Porcine Reproductive and Respiratory Syndrome Virus Viral Ovarian Tumor Domain Protease Specificity for Ubiquitin and Interferon Stimulated Gene Product 15.

Authors:  Stephanie M Bester; Courtney M Daczkowski; Kay S Faaberg; Scott D Pegan
Journal:  ACS Infect Dis       Date:  2018-06-12       Impact factor: 5.084

2.  Inherent dynamics within the Crimean-Congo Hemorrhagic fever virus protease are localized to the same region as substrate interactions.

Authors:  Elan Z Eisenmesser; Glenn C Capodagli; Geoffrey S Armstrong; Michael J Holliday; Nancy G Isern; Fengli Zhang; Scott D Pegan
Journal:  Protein Sci       Date:  2015-01-28       Impact factor: 6.725

3.  Biochemical and Structural Insights into the Preference of Nairoviral DeISGylases for Interferon-Stimulated Gene Product 15 Originating from Certain Species.

Authors:  M K Deaton; J V Dzimianski; C M Daczkowski; G K Whitney; N J Mank; M M Parham; E Bergeron; S D Pegan
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

4.  Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.

Authors:  Florine E M Scholte; Marko Zivcec; John V Dzimianski; Michelle K Deaton; Jessica R Spengler; Stephen R Welch; Stuart T Nichol; Scott D Pegan; Christina F Spiropoulou; Éric Bergeron
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

5.  A Naturally Occurring Recombinant Enterovirus Expresses a Torovirus Deubiquitinase.

Authors:  Pengcheng Shang; Saurav Misra; Ben Hause; Ying Fang
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

6.  Flipping the substrate preference of Hazara virus ovarian tumour domain protease through structure-based mutagenesis.

Authors:  John V Dzimianski; Savannah L Mace; Isabelle L Williams; Brendan T Freitas; Scott D Pegan
Journal:  Acta Crystallogr D Struct Biol       Date:  2020-10-16       Impact factor: 7.652

7.  Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.

Authors:  Courtney M Daczkowski; Octavia Y Goodwin; John V Dzimianski; Jonathan J Farhat; Scott D Pegan
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

8.  Fluorometric CCHFV OTU protease assay with potent inhibitors.

Authors:  Fatih Kocabas; Galip S Aslan
Journal:  Virus Genes       Date:  2015-07-09       Impact factor: 2.332

9.  The vOTU domain of highly-pathogenic porcine reproductive and respiratory syndrome virus displays a differential substrate preference.

Authors:  Michelle K Deaton; Allyn Spear; Kay S Faaberg; Scott D Pegan
Journal:  Virology       Date:  2014-03-15       Impact factor: 3.616

10.  Second International Conference on Crimean-Congo Hemorrhagic Fever.

Authors:  Jessica R Spengler; Dennis A Bente; Mike Bray; Felicity Burt; Roger Hewson; Gülay Korukluoglu; Ali Mirazimi; Friedemann Weber; Anna Papa
Journal:  Antiviral Res       Date:  2017-12-02       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.